Risk of tuberculosis infection in anti-TNF-α biological therapy: From bench to bedside

Journal of Microbiology, Immunology and Infection

Volumn 47, Issue 4, 2014, Pages 268-274

  Xie, Xi ^a   Li, Fen ^a   Chen, Jin Wei ^a   Wang, Jia ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Anti TNF ; Biological therapy; Tuberculosis

Indexed keywords

ABATACEPT; ADALIMUMAB; CERTOLIZUMAB PEGOL; DACLIZUMAB; EFALIZUMAB; ETANERCEPT; HEMAGGLUTININ; HEPARIN BINDING HEMAGGLUTININ; INFLIXIMAB; MYCOBACTERIUM ANTIGEN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ALCOHOLISM; BACTERIAL LOAD; BACTERIAL VIRULENCE; COMPARATIVE EFFECTIVENESS; DIABETES MELLITUS; HUMAN; IMMUNOTHERAPY; INCIDENCE; INFECTION RISK; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS TEST KIT; NONHUMAN; REVIEW; RISK FACTOR; RISK REDUCTION; SERODIAGNOSIS; SMOKING; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOSIS CONTROL; ADVERSE EFFECTS; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL THERAPY; IMMUNOLOGY; MYCOBACTERIUM TUBERCULOSIS; RISK; TRANSLATIONAL RESEARCH;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOLOGICAL THERAPY; HUMANS; LATENT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; RECEPTORS, TUMOR NECROSIS FACTOR; RISK; RISK FACTORS; TRANSLATIONAL MEDICAL RESEARCH; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84904473311     PISSN: 16841182     EISSN: 19959133     Source Type: Journal    
DOI: 10.1016/j.jmii.2013.03.005     Document Type: Review

References (61)

1. Roach D.R., Bean A.G., Demangel C., France M.P., Briscoe H., Britton W.J. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 2002, 168:4620-4627.
2. Bruns H., Meinken C., Schauenberg P., Harter G., Kern P., Modlin R.L., et al. Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans. J Clin Invest 2009, 119:1167-1177.
3. Galloway J.B., Hyrich K.L., Mercer L.K., Dixon W.G., Fu B., Ustianowski A.P., et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 2011, 50:124-131.
4. Tubach F., Salmon D., Ravaud P., Allanore Y., Goupille P., Breban M., et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009, 60:1884-1894.
5. Taylor Z., Nolan C.M., Blumberg H.M. Controlling tuberculosis in the United States. Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America. MMWR Recomm Rep 2005, 54:1-81.
6. Jensen P.A., Lambert L.A., Iademarco M.F., Ridzon R. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR Recomm Rep 2005, 54:1-141.
7. Hauck F.R., Neese B.H., Panchal A.S., El-Amin W. Identification and management of latent tuberculosis infection. Am Fam Physician 2009, 79:879-886.
8. Wood R., Maartens G., Lombard C.J. Risk factors for developing tuberculosis in HIV-1-infected adults from communities with a low or very high incidence of tuberculosis. J Acquir Immune Defic Syndr 2000, 23:75-80.
9. Girardi E., Antonucci G., Ippolito G., Raviglione M.C., Rapiti E., Di Perri G., et al. Association of tuberculosis risk with the degree of tuberculin reaction in HIV-infected patients. The Gruppo Italiano di Studio Tubercolosi e AIDS. Arch Intern Med 1997, 157:797-800.
10. Antonucci G., Girardi E., Raviglione M.C., Ippolito G. Risk factors for tuberculosis in HIV-infected persons. A prospective cohort study. The Gruppo Italiano di Studio Tubercolosi e AIDS (GISTA). JAMA 1995, 274:143-148.
11. Canet E., Dantal J., Blancho G., Hourmant M., Coupel S. Tuberculosis following kidney transplantation: clinical features and outcome. A French multicentre experience in the last 20 years. Nephrol Dial Transplant 2011, 26:3773-3778.
12. Torre-Cisneros J., Doblas A., Aguado J.M., San Juan R., Blanes M., Montejo M., et al. Tuberculosis after solid-organ transplant: incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) cohort. Clin Infect Dis 2009, 48:1657-1665.
13. Erkens C.G., Kamphorst M., Abubakar I., Bothamley G.H., Chemtob D., Haas W., et al. Tuberculosis contact investigation in low prevalence countries: a European consensus. Eur Respir J 2010, 36:925-949.
14. Brassard P., Kezouh A., Suissa S. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis 2006, 43:717-722.
15. Seong S.S., Choi C.B., Woo J.H., Bae K.W., Joung C.L., Uhm W.S., et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol 2007, 34:706-711.
16. Wallis R.S., Broder M.S., Wong J.Y., Hanson M.E., Beenhouwer D.O. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004, 38:1261-1265.
17. Kaplan M.H., Armstrong D., Rosen P. Tuberculosis complicating neoplastic disease. A review of 201 cases. Cancer 1974, 33:850-858.
18. Kim S.J., Hong Y.P., Lew W.J., Yang S.C., Lee E.G. Incidence of pulmonary tuberculosis among diabetics. Tuber Lung Dis 1995, 76:529-533.
19. Slama K., Chiang C.Y., Enarson D.A., Hassmiller K., Fanning A., Gupta P., et al. Tobacco and tuberculosis: a qualitative systematic review and meta-analysis. Int J Tuberc Lung Dis 2007, 11:1049-1061.
20. Lonnroth K., Williams B.G., Stadlin S., Jaramillo E., Dye C. Alcohol use as a risk factor for tuberculosis - a systematic review. BMC Public Health 2008, 8:289.
21. Sfriso P., Ghirardello A., Botsios C., Tonon M., Zen M., Bassi N., et al. Infections and autoimmunity: the multifaceted relationship. J Leukoc Biol 2010, 87:385-395.
22. Solovic I., Sester M., Gomez-Reino J.J., Rieder H.L., Ehlers S., Milburn H.J., et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 2010, 36:1185-1206.
23. Galloway J.B., Hyrich K.L., Mercer L.K., Dixon W.G., Watson K.D., Lunt M., et al. The risk of serious infections in patients receiving anakinra for rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2011, 50:1341-1342.
24. Singh J.A., Wells G.A., Christensen R., Tanjong Ghogomu E., Maxwell L., Macdonald J.K., et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011, 16:CD008794.
25. Buch M.H., Smolen J.S., Betteridge N., Breedveld F.C., Burmester G., Dorner T., et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011, 70:909-920.
26. Langley R.G., Carey W.P., Rafal E.S., Tyring S.K., Caro I., Wang X., et al. Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience. Clin Ther 2005, 27:1317-1328.
27. Perales M.A., Ishill N., Lomazow W.A., Weinstock D.M., Papadopoulos E.B., Dastigir H., et al. Long-term follow-up of patients treated with daclizumab for steroid-refractory acute graft-vs-host disease. Bone Marrow Transplant 2007, 40:481-486.
28. Wallis R.S. Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade. Arthritis Rheum 2008, 58:947-952.
29. Dixon W.G., Hyrich K.L., Watson K.D., Lunt M., Galloway J., Ustianowski A., et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010, 69:522-528.
30. Keystone E.C., Papp K.A., Wobeser W. Challenges in diagnosing latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. J Rheumatol 2011, 38:1234-1243.
31. Chan E.D., Bai X., Kartalija M., Orme I.M., Ordway D.J. Host immune response to rapidly growing mycobacteria, an emerging cause of chronic lung disease. Am J Respir Cell Mol Biol 2010, 43:387-393.
32. Tena-Coki N.G., Scriba T.J., Peteni N., Eley B., Wilkinson R.J., Andersen P., et al. CD4 and CD8 T-cell responses to mycobacterial antigens in African children. Am J Respir Crit Care Med 2010, 182:120-129.
33. Beenhouwer D., Wallis R., Broder M., Furst D.E. Mechanisms of action of tumor necrosis factor antagonist and granulomatous infections. J Rheumatol 2004, 31:1888-1892.
34. Tracey D., Klareskog L., Sasso E.H., Salfeld J.G., Tak P.P. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008, 117:244-279.
35. Wallis R.S. Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis 2008, 8:601-611.
36. Plessner H.L., Lin P.L., Kohno T., Louie J.S., Kirschner D., Chan J., et al. Neutralization of tumor necrosis factor (TNF) by antibody but not TNF receptor fusion molecule exacerbates chronic murine tuberculosis. J Infect Dis 2007, 195:1643-1650.
37. Chakravarty S.D., Zhu G., Tsai M.C., Mohan V.P., Marino S., Kirschner D.E., et al. Tumor necrosis factor blockade in chronic murine tuberculosis enhances granulomatous inflammation and disorganizes granulomas in the lungs. Infect Immun 2008, 76:916-926.
38. Lin P.L., Myers A., Smith L., Bigbee C., Bigbee M., Fuhrman C., et al. Tumor necrosis factor neutralization results in disseminated disease in acute and latent Mycobacterium tuberculosis infection with normal granuloma structure in a cynomolgus macaque model. Arthritis Rheum 2010, 62:340-350.
39. Saliu O.Y., Sofer C., Stein D.S., Schwander S.K., Wallis R.S. Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity. J Infect Dis 2006, 194:486-492.
40. Yun J.W., Lim S.Y., Suh G.Y., Chung M.P., Kim H., Kwon O.J., et al. Diagnosis and treatment of latent tuberculosis infection in arthritis patients treated with tumor necrosis factor antagonists in Korea. J Korean Med Sci 2007, 22:779-783.
41. Carmona L., Gomez-Reino J.J., Rodriguez-Valverde V., Montero D., Pascual-Gomez E., Mola E.M., et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005, 52:1766-1772.
42. Recommendations about prevention and management of tuberculosis before infliximab treatment. Chin J Intern Med 2009, 48:980-982. Consensus report of Chinese infliximab study group.
43. Recommendations about TNF-α antagonist etanercept treatment of rheumatoid arthritis and ankylosing spondylitis. Chin J Intern Med 2010, 49:546-549. Consensus report of Chinese etanercept study group.
44. Liu J., Zhang S., Tan S., Zheng B., Gao G.F. Revival of the identification of cytotoxic T-lymphocyte epitopes for immunological diagnosis, therapy and vaccine development. Exp Biol Med (Maywood) 2011, 236:253-267.
45. Behr M.A., Wilson M.A., Gill W.P., Salamon H., Schoolnik G.K., Rane S., et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 1999, 284:1520-1523.
46. Sutherland J.S., de Jong B.C., Jeffries D.J., Adetifa I.M., Ota M.O. Production of TNF-alpha, IL-12(p40) and IL-17 can discriminate between active TB disease and latent infection in a West African cohort. PLoS One 2010, 5:e12365.
47. Kobashi Y., Sugiu T., Shimizu H., Ohue Y., Mouri K., Obase Y., et al. Clinical evaluation of the T-SPOT.TB test for patients with indeterminate results on the QuantiFERON TB-2G test. Intern Med 2009, 48:137-142.
48. Chang K.C., Leung C.C. Systematic review of interferon-gamma release assays in tuberculosis: focus on likelihood ratios. Thorax 2010, 65:271-276.
49. Lee J.Y., Choi H.J., Park I.N., Hong S.B., Oh Y.M., Lim C.M., et al. Comparison of two commercial interferon-gamma assays for diagnosing Mycobacterium tuberculosis infection. Eur Respir J 2006, 28:24-30.
50. Menzies D., Pai M., Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 2007, 146:340-354.
51. Jiang W., Shao L., Zhang Y., Zhang S., Meng C., Xu Y., et al. High-sensitive and rapid detection of Mycobacterium tuberculosis infection by IFN-gamma release assay among HIV-infected individuals in BCG-vaccinated area. BMC Immunol 2009, 10:31.
52. Casas S., Andreu A., Juanola X., Bordas X., Alcaide F., Moure R., et al. Diagnosis of tuberculosis infection by tuberculin skin test and a whole-blood interferon-gamma release assay in patients considered for anti-tumor necrosis factor-alpha therapy. Diagn Microbiol Infect Dis 2011, 71:57-65.
53. Mazurek G.H., Jereb J., Vernon A., LoBue P., Goldberg S., Castro K. Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States. MMWR Recomm Rep 2010, 2010(59):1-25.
54. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control 2006, National Collaborating Centre for Chronic Conditions (UK), Royal College of Physicians (UK), London, Available from:, [accessed 10.04.12]. http://www.ncbi.nlm.nih.gov/books/NBK45802/.
55. Chang B., Park H.Y., Jeon K., Ahn J.K., Cha H.S., Koh E.M., et al. Interferon-gamma release assay in the diagnosis of latent tuberculosis infection in arthritis patients treated with tumor necrosis factor antagonists in Korea. Clin Rheumatol 2011, 30:1535-1541.
56. van Zyl-Smit R.N., Pai M., Peprah K., Meldau R., Kieck J., Juritz J., et al. Within-subject variability and boosting of T-cell interferon-gamma responses after tuberculin skin testing. Am J Respir Crit Care Med 2009, 180:49-58.
57. Place S., Verscheure V., de San N., Hougardy J.M., Schepers K., Dirix V., et al. Heparin-binding, hemagglutinin-specific IFN-gamma synthesis at the site of infection during active tuberculosis in humans. Am J Respir Crit Care Med 2010, 182:848-854.
58. Berry M.P., Graham C.M., McNab F.W., Xu Z., Bloch S.A., Oni T., et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010, 466:973-977.
59. Aggarwal R., Manadan A.M., Poliyedath A., Sequeira W., Block J.A. Safety of etanercept in patients at high risk for mycobacterial tuberculosis infections. J Rheumatol 2009, 36:914-917.
60. Takeuchi T., Tatsuki Y., Nogami Y., Ishiguro N., Tanaka Y., Yamanaka H., et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 2008, 67:189-194.
61. Sichletidis L., Settas L., Spyratos D., Chloros D., Patakas D. Tuberculosis in patients receiving anti-TNF agents despitechemoprophylaxis. Int J Tuberc Lung Dis 2006, 10:1127-1132.